Call Us: (1) 608 441-2729 - Email Us email@example.com
M2SR: The Vaccine
Board of Directors
Clinical Advisory Board
News and opinions
FluGen Co-Founder Dr. Yoshihiro Kawoaka Elected to the National Academy of Sciences
May 1, 2013
Share this Story
Comments are closed.
UW–Madison, FluGen, Bharat Biotech to develop CoroFlu, a coronavirus vaccine
Single-replication BM2SR vaccine provides sterilizing immunity and cross-lineage influenza B virus protection in mice
FluGen’s M2SR Phase 2 Human Challenge Trial Initial Results
Flu shots urged as Madison’s FluGen plays role in effort for universal vaccine
FluGen completes dosing of phase 2 study to assess effectiveness of novel influenza vaccine designed to protect against mismatched strains
(c)2016 FluGen, Inc. All rights reserved.
Back to Top
Enter your Infotext or Widgets here...